Stock PROK PROKIDNEY CORP.
Add to a list
To use this feature you must be a member
Log inSign up

News ProKidney Corp.

Equities

PROK

KYG7S53R1049

End-of-day quote Nasdaq
Other stock markets
 06:00:00 2024-05-22 pm EDT 		5-day change 1st Jan Change
3.51 USD -3.04% Intraday chart for ProKidney Corp. -13.44% +97.19%
May. 10 ProKidney Q1 Loss Unchanged From Year Earlier MT
May. 10 ProKidney Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
ProKidney to Host Virtual KOL Event to Discuss Current Treatment Landscape of Chronic Kidney Disease Caused by Diabetes and Data from Phase 2 RMCL-002 Clinical Trial on May 28, 2024
AQ
ProKidney Reports Business Updates and First Quarter 2024 Financial Results
AQ
ProKidney Q1 Loss Unchanged From Year Earlier
MT
ProKidney Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
ProKidney Reports Business Updates and First Quarter 2024 Financial Results
AQ
ProKidney Announces Key Leadership Appointments Strengthening Clinical and Technical Operations
AQ
ProKidney Corp. Announces Key Leadership Appointments Strengthening Clinical and Technical Operations
CI
ProKidney Posts Wider 2023 Loss
MT
ProKidney Corp. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
ProKidney Reports Full Year 2023 Financial Results and Recent Corporate Highlights
AQ
ProKidney to Participate in Jefferies Biotech on the Bay Summit
AQ
BofA Securities Downgrades ProKidney to Neutral From Buy, Cuts Price Target to $2 From $8
MT
Chronic Kidney Disease Pipeline, FDA Approvals, Clinical Trials Developments, Companies 2023 | Boehringer Ingelheim, Eli Lilly and Company, Reata Pharmaceuticals, Novo Nordisk, Prokidney, and others.
AQ
ProKidney Corp. Announces Termination of Deepak Jain as Chief Operating Officer
CI
ProKidney Appoints Nikhil Pereira-Kamath, MBA, as Chief Business Officer
AQ
Prokidney Appoints Nikhil Pereira-Kamath as Chief Business Officer
CI
ProKidney Files $500 Million Mixed Shelf
MT
Prokidney Insider Sold Shares Worth $9,498,584, According to a Recent SEC Filing
MT
ProKidney to Participate in a Fireside Chat at the Upcoming Evercore ISI 6th Annual HEALTHCONx Conference
AQ
Sector Update: Health Care Stocks Advance in Late Afternoon Trading
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PROK Stock
  4. News ProKidney Corp.